Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACST

Acasti Pharma (ACST) Stock Price, News & Analysis

Acasti Pharma logo

About Acasti Pharma Stock (NASDAQ:ACST)

Advanced Chart

Key Stats

Today's Range
$3.03
$3.14
50-Day Range
$2.56
$3.60
52-Week Range
$1.98
$3.60
Volume
12,261 shs
Average Volume
22,722 shs
Market Capitalization
$29.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Stock News Headlines

This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)
See More Headlines

ACST Stock Analysis - Frequently Asked Questions

Acasti Pharma Inc. (NASDAQ:ACST) issued its quarterly earnings data on Friday, June, 21st. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.30.

Acasti Pharma's stock reverse split on the morning of Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
6/21/2024
Today
5/29/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACST
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+221.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.85 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$6.57 per share
Price / Book
0.47

Miscellaneous

Free Float
8,770,000
Market Cap
$29.23 million
Optionable
Not Optionable
Beta
1.52
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ACST) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners